SK Group Chairman Chey Tae-won conducted inspections of the US operations of the group's chip materials and biopharma affiliates, as reported by the SK Supex Council. During his stay in the US, which began on June 22, Chey met with CEOs of major tech companies and visited the headquarters of SK Life Science and Absolics to oversee their production lines and gather information on sales. Chey's visit to SK Life Science in New Jersey on July 2 focused on a briefing about the sales of Xcopri, a drug for managing partial-onset seizures in adults with epilepsy. The drug has achieved significant success in the US market since its launch in May 2020, with over 100,000 patients prescribed the medicine. Additionally, Chey emphasized the importance of closely monitoring potential impacts of US policy changes, particularly those related to countering China's influence, and encouraged employees to devise appropriate response measures. Furthermore, Chey visited Absolics in Georgia to inspect the factory where the world's first glass substrate product is set to be mass-produced. This new technology is expected to enhance the performance and power efficiency of semiconductors for high-performance computing and AI applications. In meetings with tech CEOs, Chey promoted the advanced technology of Absolics and emphasized the significance of AI for SK Group's future growth. His trip's outcomes will lead to follow-up measures by SK Group affiliates to strengthen the group's AI ecosystem in collaboration with major tech partners.